Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update

Turnstone Biologics Corp. (NASDAQ:TSBX) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 548,700 shares, a decline of 21.9% from the November 15th total of 702,900 shares. Approximately 4.0% of the shares of the company are short sold. Based on an average daily trading volume, of 271,500 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Trading of Turnstone Biologics

A hedge fund recently raised its stake in Turnstone Biologics stock. FMR LLC increased its stake in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,172,987 shares of the company’s stock after purchasing an additional 37,738 shares during the period. FMR LLC owned approximately 5.07% of Turnstone Biologics worth $653,000 as of its most recent filing with the Securities & Exchange Commission. 52.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on TSBX shares. Bank of America lowered Turnstone Biologics from a “neutral” rating to an “underperform” rating in a research note on Friday, November 15th. Piper Sandler cut their price target on shares of Turnstone Biologics from $20.00 to $3.75 and set an “overweight” rating on the stock in a report on Monday, August 19th.

Turnstone Biologics Stock Performance

Shares of TSBX opened at $0.48 on Friday. Turnstone Biologics has a fifty-two week low of $0.40 and a fifty-two week high of $5.75. The firm’s 50-day simple moving average is $0.50 and its two-hundred day simple moving average is $1.34.

Turnstone Biologics (NASDAQ:TSBX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.13. As a group, equities analysts expect that Turnstone Biologics will post -3.75 earnings per share for the current fiscal year.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.